Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Sweden Joins Campaign for Post-Brexit Host of EMA

XTALKS VITALS NEWS

Sweden

Sweden joins multiple other countries, including France, Spain and Poland, which are bidding to be the new home of the regulatory agency, post-Brexit.

Share this!

December 14, 2016 | by Sarah Hand, M.Sc.

Last week, the Swedish government joined the competition to become the new host country of the European Medicines Agency (EMA). Sweden joins multiple other countries, including France, Spain and Poland, which are bidding to be the new home of the regulatory agency, post-Brexit.

Currently, the EMA is headquartered in London, England, however this will need to change as the country has voted to leave the European Union (EU). Denmark, Italy and Ireland have also nominated themselves for the position.



“With one of Europe's top national medicines agencies, an excellent climate for research and life science as well as good conditions for an efficient relocation, Sweden is a good future home for the EMA,” said Gabriel Wikstrom, Sweden’s Health Care Minister, in a statement. By having the EMA close to Sweden’s capital Stockholm, the country could see a major boost in the pharmaceutical and biotech sectors.

Sweden lost a major player in the industry when multinational pharmaceutical company AstraZeneca relocated its headquarters to England. Still, the country boasts a number of small medtech companies who thrive in the country’s startup environment.

Sweden is already the home of the European Centre for Disease Prevention and Control (ECDC), which could make it a logical choice for the new site of the EMA. The EMA comprises over 900 employees, which will eventually need to be relocated with minimal effect on day-to-day operations including drug approvals.

As the UK has yet to start the process of exiting from the EU, the decision of where the EMA should be based is unlikely to be made anytime soon. In June of this year, 52 percent of the UK voted in favour of leaving the EU.


Keywords: Brexit, EMA, Regulatory Agency


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News


Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News


Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

One Patient’s Perspective on Clinical Trials

REGISTER FOR THESE WEBINARS

Planning and Conducting Trials of the Latest Immunotherapies


ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation


Medical Devices: Reviewing Regulatory Changes in the US and EU


Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.